API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
USA (Orange Book)
0
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
VIRALEX (inosine pranobex) is an immunomodulatory agent with antiviral activity across a broad spectrum. It boosts the body’s defenses against viral infections by enhancing both innate and adaptive immunity.
Lead Product(s): Inosine Pranobex
Therapeutic Area: Infections and Infectious Diseases Product Name: Viralex
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Details:
Approval for VIRALEX® (Inosine pranobex) is based on the results of Phase 3 trial demonstrated, 80.17% of patients treated with VIRALEX® showed clinical improvement on day 6, which is significantly higher (p<0.001) from that in the controlled group.
Lead Product(s): Inosine Pranobex
Therapeutic Area: Infections and Infectious Diseases Product Name: Viralex
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2022